0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mode of action studies confirm on-target engagement of lysyl-tRNA synthetase inhibitor and lead to new selection marker for Cryptosporidium

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Cryptosporidiosis is a leading cause of diarrheal-associated morbidity and mortality, predominantly affecting children under 5 years old in low-and-middle-income countries. There is no effective treatment and no vaccine. New therapeutics are emerging from drug discovery efforts. It is critical that mode of action studies are performed alongside drug discovery to ensure the best clinical outcomes. Unfortunately, technology to identify and validate drug targets for Cryptosporidium is severely lacking.

          Methods

          We used C. parvum lysyl-tRNA synthetase ( CpKRS) and DDD01510706 as a target-compound pair to develop both chemical and genetic tools for mode of action studies for Cryptosporidium. We adapted thermal proteome profiling (TPP) for Cryptosporidium, an unbiased approach for target identification.

          Results

          Using TPP we identified the molecular target of DDD01510706 and confirm that it is CpKRS. Genetic tools confirm that CpKRS is expressed throughout the life cycle and that this target is essential for parasite survival. Parasites genetically modified to over-express CpKRS or parasites with a mutation at the compound-binding site are resistant to treatment with DDD01510706. We leveraged these mutations to generate a second drug selection marker for genetic modification of Cryptosporidium, KRS R. This second selection marker is interchangeable with the original selection marker, Neo R, and expands the range of reverse genetic approaches available to study parasite biology. Due to the sexual nature of the Cryptosporidium life cycle, parental strains containing different drug selection markers can be crossed in vivo.

          Discussion

          Selection with both drug markers produces highly efficient genetic crosses (>99% hybrid progeny), paving the way for forward genetics approaches in Cryptosporidium.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.

          Efficient analysis of very large amounts of raw data for peptide identification and protein quantification is a principal challenge in mass spectrometry (MS)-based proteomics. Here we describe MaxQuant, an integrated suite of algorithms specifically developed for high-resolution, quantitative MS data. Using correlation analysis and graph theory, MaxQuant detects peaks, isotope clusters and stable amino acid isotope-labeled (SILAC) peptide pairs as three-dimensional objects in m/z, elution time and signal intensity space. By integrating multiple mass measurements and correcting for linear and nonlinear mass offsets, we achieve mass accuracy in the p.p.b. range, a sixfold increase over standard techniques. We increase the proportion of identified fragmentation spectra to 73% for SILAC peptide pairs via unambiguous assignment of isotope and missed-cleavage state and individual mass precision. MaxQuant automatically quantifies several hundred thousand peptides per SILAC-proteome experiment and allows statistically robust identification and quantification of >4,000 proteins in mammalian cell lysates.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The PRIDE database and related tools and resources in 2019: improving support for quantification data

            Abstract The PRoteomics IDEntifications (PRIDE) database (https://www.ebi.ac.uk/pride/) is the world’s largest data repository of mass spectrometry-based proteomics data, and is one of the founding members of the global ProteomeXchange (PX) consortium. In this manuscript, we summarize the developments in PRIDE resources and related tools since the previous update manuscript was published in Nucleic Acids Research in 2016. In the last 3 years, public data sharing through PRIDE (as part of PX) has definitely become the norm in the field. In parallel, data re-use of public proteomics data has increased enormously, with multiple applications. We first describe the new architecture of PRIDE Archive, the archival component of PRIDE. PRIDE Archive and the related data submission framework have been further developed to support the increase in submitted data volumes and additional data types. A new scalable and fault tolerant storage backend, Application Programming Interface and web interface have been implemented, as a part of an ongoing process. Additionally, we emphasize the improved support for quantitative proteomics data through the mzTab format. At last, we outline key statistics on the current data contents and volume of downloads, and how PRIDE data are starting to be disseminated to added-value resources including Ensembl, UniProt and Expression Atlas.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

              Diarrhoeal diseases cause illness and death among children younger than 5 years in low-income countries. We designed the Global Enteric Multicenter Study (GEMS) to identify the aetiology and population-based burden of paediatric diarrhoeal disease in sub-Saharan Africa and south Asia. The GEMS is a 3-year, prospective, age-stratified, matched case-control study of moderate-to-severe diarrhoea in children aged 0-59 months residing in censused populations at four sites in Africa and three in Asia. We recruited children with moderate-to-severe diarrhoea seeking care at health centres along with one to three randomly selected matched community control children without diarrhoea. From patients with moderate-to-severe diarrhoea and controls, we obtained clinical and epidemiological data, anthropometric measurements, and a faecal sample to identify enteropathogens at enrolment; one follow-up home visit was made about 60 days later to ascertain vital status, clinical outcome, and interval growth. We enrolled 9439 children with moderate-to-severe diarrhoea and 13,129 control children without diarrhoea. By analysing adjusted population attributable fractions, most attributable cases of moderate-to-severe diarrhoea were due to four pathogens: rotavirus, Cryptosporidium, enterotoxigenic Escherichia coli producing heat-stable toxin (ST-ETEC; with or without co-expression of heat-labile enterotoxin), and Shigella. Other pathogens were important in selected sites (eg, Aeromonas, Vibrio cholerae O1, Campylobacter jejuni). Odds of dying during follow-up were 8·5-fold higher in patients with moderate-to-severe diarrhoea than in controls (odd ratio 8·5, 95% CI 5·8-12·5, p<0·0001); most deaths (167 [87·9%]) occurred during the first 2 years of life. Pathogens associated with increased risk of case death were ST-ETEC (hazard ratio [HR] 1·9; 0·99-3·5) and typical enteropathogenic E coli (HR 2·6; 1·6-4·1) in infants aged 0-11 months, and Cryptosporidium (HR 2·3; 1·3-4·3) in toddlers aged 12-23 months. Interventions targeting five pathogens (rotavirus, Shigella, ST-ETEC, Cryptosporidium, typical enteropathogenic E coli) can substantially reduce the burden of moderate-to-severe diarrhoea. New methods and accelerated implementation of existing interventions (rotavirus vaccine and zinc) are needed to prevent disease and improve outcomes. The Bill & Melinda Gates Foundation. Copyright © 2013 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Cell Infect Microbiol
                Front Cell Infect Microbiol
                Front. Cell. Infect. Microbiol.
                Frontiers in Cellular and Infection Microbiology
                Frontiers Media S.A.
                2235-2988
                04 August 2023
                2023
                : 13
                : 1236814
                Affiliations
                [1] 1Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee , Dundee, United Kingdom
                [2] 2Drug Discovery Unit, School of Life Sciences, University of Dundee , Dundee, United Kingdom
                Author notes

                Edited by: Aditya S. Paul, Harvard University, United States

                Reviewed by: Guan Zhu, Jilin University, China; Adam Sateriale, The Francis Crick Institute, United Kingdom

                *Correspondence: Mattie C. Pawlowic, mcpawlowic@ 123456dundee.ac.uk ; Susan Wyllie, s.wyllie@ 123456dundee.ac.uk

                †Present addresses: Jack C. Hanna, Wellcome Centre for Integrative Parasitology, School of Infection and Immunity, University of Glasgow. United Kingdom; Ross Bacchetti, Scottish Microbiology Reference Laboratories, Glasgow Royal Infirmary, Glasgow, United Kingdom

                ‡These authors have contributed equally to this work

                Article
                10.3389/fcimb.2023.1236814
                10436570
                37600947
                fac563fe-3587-4619-9ab5-e7bcdda90442
                Copyright © 2023 Hanna, Corpas-Lopez, Seizova, Colon, Bacchetti, Hall, Sands, Robinson, Baragaña, Wyllie and Pawlowic

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 08 June 2023
                : 10 July 2023
                Page count
                Figures: 4, Tables: 0, Equations: 0, References: 66, Pages: 14, Words: 8990
                Funding
                Funded by: Wellcome Trust , doi 10.13039/100010269;
                Award ID: 218448/Z/19/Z, 203134/Z/16/Z, 213469/Z/18/Z, 204816/Z/16/Z
                Funded by: Medical Research Council , doi 10.13039/501100000265;
                Award ID: MR/N013735/1
                Funded by: Carnegie Trust for the Universities of Scotland , doi 10.13039/501100000582;
                Award ID: 213469/Z/18/Z
                Funded by: Royal Society , doi 10.13039/501100000288;
                Award ID: RIG008676
                JCH is supported by the Medical Research Council (MR/N013735/1). This work was funded in part from the Wellcome Trust (Innovations Award to SW and MCP [218448/Z/19/Z], a Centre Award [203134/Z/16/Z and 223608/Z/21/Z], an Institutional Strategic Support Fund [204816/Z/16/Z] and a PhD studentship to EMS (102132/B/13/Z)]). This work was funded in part by a Sir Henry Dale Fellowship from the Wellcome Trust and the Royal Society to MCP (213469/Z/18/Z), and from the Carnegie Trust (Research Incentive Grant to MCP [RIG008676]). GMJH is supported by the Medical Research Council (MR/R015791/1).
                Categories
                Cellular and Infection Microbiology
                Original Research
                Custom metadata
                Parasite and Host

                Infectious disease & Microbiology
                cryptosporidiosis,mode of action,aminoacyl-trna synthtase,trna synthetase inhibitor,selection marker,genetic cross,thermal proteome profiling (tpp)

                Comments

                Comment on this article